Perkins spinout company reports positive clinical trial results

12 July 2017

Dimerix Limited, a company founded on technology developed by researchers at the Harry Perkins Institute of Medical Research, today announced positive safety and efficacy data following its Phase 2a clinical trials.

Associate Professor Kevin PflegerThe trial was designed to determine if Dimerix’s flagship treatment, DMX-200, was safe for use in patients experiencing Chronic Kidney Disease.

Chronic Kidney Disease is an illness that affects 1.7 million Australians each year and can lead to kidney failure, cardiovascular disease and premature death.

The treatment aims to control protein leakage (proteinuria) from the kidneys, a common symptom of chronic kidney disease and a predictor for the decline of kidney function - higher levels of proteinuria signify a rapid decline of kidney health.

The trial results announced today show that patient safety and tolerability were demonstrated, and 25% of patients experienced a reduction in proteinuria of 50% beyond that achieved with current standard of care therapy.

Perkins researcher and Chief Scientific Advisor of Dimerix, Associate Professor Kevin Pfleger, said he was delighted that the results indicate the treatment is having a significant impact in slowing the progression of Chronic Kidney Disease.

“CKD is considered a progressive disease, meaning that without appropriate treatment, a patient’s proteinuria levels will get worse over time. This is thought to be because excess protein damages the kidneys, leading to further protein leakage. This creates a downward spiral of worsening kidney function and further kidney damage,” Associate Professor Pfleger said.

“If we can further demonstrate that DMX-200 reduces proteinuria levels, preventing further kidney deterioration and the need for blood dialysis, we will have made a meaningful advancement in treatment options for patients over the current highest standard of care.”

“Given this is a “hard to treat” patient group, the results are especially promising. The prevalence of CKD is rising and in most cases, residual proteinuria continues even with the best use of existing treatments. As such, treatments designed to further reduce, or eliminate, proteinuria, are eagerly sought and my hope is that Dimerix can provide this.”

The clinical trial will now progress into Phase 2b, which is expected to start by the end of 2017.

Associate Professor Pfleger was recently awarded two 40-under-40 awards for his outstanding work, leadership and entrepreneurship in medial research. 

Back To Top